Clinical Trials Logo

Primary Biliary Cholangitis clinical trials

View clinical trials related to Primary Biliary Cholangitis.

Filter by:

NCT ID: NCT04618575 Recruiting - Hepatitis Clinical Trials

Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1

Start date: March 17, 2021
Phase: Phase 4
Study type: Interventional

A randomized controlled open-label clinical trial of ursodeoxycholic acid combined with total glucosides of paeony in the treatment of PBC with AIH features 1

NCT ID: NCT04617561 Recruiting - Clinical trials for Primary Biliary Cholangitis

Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II

Start date: November 1, 2020
Phase: Phase 4
Study type: Interventional

A randomized controlled open-label clinical trial of ursodeoxycholic acid combined with low dose glucocorticoid in the treatment of PBC With AIH Features II to asses efficacy and safety.

NCT ID: NCT04604652 Completed - Clinical trials for Primary Biliary Cirrhosis

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

PRONTO-PBC
Start date: May 27, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy. Inadequate response is defined as persistently elevated serum alkaline phosphatase at greater than or equal to1.5 times the upper limits of normal for the testing lab in spite of having been on adequate doses of standard therapy with UDCA (ursodeoxycholic acid) at 13-15 mg/kg for at least 6 months.

NCT ID: NCT04594694 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Start date: October 2, 2019
Phase: Phase 2
Study type: Interventional

Study to evaluate the efficacy, safety, and tolerability of investigational drug obeticholic acid (OCA) in combination with the investigational drug bezafibrate (BZF) in participants with Primary Biliary Cholangitis (PBC).

NCT ID: NCT04376528 Recruiting - Immunosuppression Clinical Trials

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

Start date: June 16, 2021
Phase: Phase 4
Study type: Interventional

Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome induced by mycophenolate mofetil versus cyclosporin A

NCT ID: NCT04265235 Terminated - Clinical trials for Primary Biliary Cholangitis

EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study

EXCITED
Start date: April 7, 2019
Phase: N/A
Study type: Interventional

A prospective, single centre, single-arm, pilot study investigating the safety and efficacy of a 12-week remotely-monitored home-based exercise program in patients with refractory fatigue (based on PBC-40 Quality of Life measure) secondary to Primary Biliary Cirrhosis.

NCT ID: NCT04076527 Recruiting - Clinical trials for Primary Biliary Cholangitis

Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis

PBC-Cohort
Start date: September 19, 2019
Phase:
Study type: Observational

The German PBC Cohort is a multi-centric, observational (non-interventional) study with three parallel groups. The main objective of this observational study is to describe the course of Primary biliary cholangitis (PBC) in patients in Germany under routine treatment with approved drugs. Therefore, the effectiveness and safety/tolerability of PBC treatment options in a real-life setting will be evaluated.

NCT ID: NCT03954327 Completed - Clinical trials for Primary Biliary Cholangitis

Combination Antiretroviral Therapy (cART) for PBC

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at unblinding. All patients will be offered an additional 12 months open label therapy. Observational, open label study will be performed in parallel using Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir in liver transplant recipients meeting all entry criteria except for use of immunosuppression.

NCT ID: NCT03742973 Terminated - Clinical trials for Primary Biliary Cholangitis

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

Start date: March 28, 2019
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).

NCT ID: NCT03703076 Recruiting - Clinical trials for Primary Biliary Cholangitis

A Post-Authorisation Non-Interventional Observational of Patients in France With Primary Biliary Cholangitis Treated With Obeticholic Acid in Real Life

OCARELIFE
Start date: April 10, 2018
Phase:
Study type: Observational

Post-authorisation non-interventional observational study of patients with Primary Biliary Cholangitis who started Ocaliva® treatment between October 1st, 2016 and December 31, 2017.